NRC HEALTH(NRC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,053 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NRC Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for NRC HEALTH (NRC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NRC at 41.6/100 on a 32-signal composite quality model, placing it at rank #2,053 of 2,962 stocks — the bottom half of the AI-ranked universe. NRC scores in the top quartile across earnings quality (97.4). Areas of concern include revenue scale (19.6) and revenue growth (20.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NRC HEALTH reports quarterly revenue of $35.4M, net income of $-3.3M, free cash flow of $62.0K. Top institutional holders of NRC by reported 13-F value include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. NRC trades on the Nasdaq exchange and files with the SEC under CIK 70487. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NRC HEALTH directly from SEC EDGAR. NRC HEALTH's 13F Pro composite quality score has ranged between 42 and 73 since 2021, currently 41.6 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$35.4M
Net Income
Q2 2026
$-3.3M
Free Cash Flow
Q2 2026
$62.0K
ROIC
Q2 2026
-13.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-4.0% YoYNet Income
-53.2% YoYOperating Income
-35.8% YoYEPS (Diluted)
+4707.7% YoYTotal Assets
+1.8% YoYTotal Debt
+36.5% YoYOp. Cash Flow
-23.6% YoYFree Cash Flow
-17.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $137.4M -4.0% | $143.1M -3.7% | $148.6M -2.0% | $151.6M +2.4% | $148.0M +11.0% | $133.3M |
| Net Income | $11.6M -53.2% | $24.8M -20.0% | $31.0M -2.6% | $31.8M -15.1% | $37.5M | — |
| Operating Income | $22.6M -35.8% | $35.2M -12.1% | $40.0M -14.0% | $46.5M -7.4% | $50.3M +17.8% | $42.7M |
| EPS (Diluted) | $50.00 +4707.7% | $1.04 -16.8% | $1.25 -1.6% | $1.27 -13.0% | $1.46 +0.7% | $1.45 |
| Total Assets | $134.9M +1.8% | $132.5M +8.3% | $122.4M -6.2% | $130.5M -17.2% | $157.5M +18.1% | $133.4M |
| Total Debt | $79.0M +36.5% | $57.9M +57.4% | $36.8M +64.9% | $22.3M -16.2% | $26.6M -13.3% | $30.7M |
| Operating Cash Flow | $26.4M -23.6% | $34.6M -9.2% | $38.1M +5.1% | $36.3M -21.7% | $46.3M +14.0% | $40.6M |
| Free Cash Flow | $15.7M -17.9% | $19.2M -14.1% | $22.3M -15.5% | $26.4M -35.3% | $40.8M +11.4% | $36.7M |
Get alerted when NRC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NRC HEALTH including:
Top Institutional Holders of NRC
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
$43.8M2,030,492 shBlackRock, Inc.
$22.9M1,061,355 shMORGAN STANLEY
$18.5M859,269 shVANGUARD CAPITAL MANAGEMENT LLC
$14.4M666,554 shDIMENSIONAL FUND ADVISORS LP
$10.6M491,228 shWillis Investment Counsel
$9.4M434,785 shGEODE CAPITAL MANAGEMENT, LLC
$9.1M420,056 shQV Investors Inc.
$8.0M372,503 shFARMERS & MERCHANTS INVESTMENTS INC
$7.1M330,649 shRENAISSANCE TECHNOLOGIES LLC
$7.0M325,384 sh
| Fund | Value | Shares |
|---|---|---|
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | $43.8M | 2,030,492 |
| BlackRock, Inc. | $22.9M | 1,061,355 |
| MORGAN STANLEY | $18.5M | 859,269 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.4M | 666,554 |
| DIMENSIONAL FUND ADVISORS LP | $10.6M | 491,228 |
| Willis Investment Counsel | $9.4M | 434,785 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.1M | 420,056 |
| QV Investors Inc. | $8.0M | 372,503 |
| FARMERS & MERCHANTS INVESTMENTS INC | $7.1M | 330,649 |
| RENAISSANCE TECHNOLOGIES LLC | $7.0M | 325,384 |
Companies Similar to NRC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PUMA BIOTECHNOLOGY, INC.
UTAH MEDICAL PRODUCTS INC
MIMEDX GROUP, INC.
HAEMONETICS CORP
Amphastar Pharmaceuticals, Inc.
Prestige Consumer Healthcare Inc.
CONMED Corp
SIGA TECHNOLOGIES INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NRC on your watchlist
Track score changes the day NRC HEALTH files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NRC a good stock to buy?
13F Pro's AI-powered analysis of NRC HEALTH (NRC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRC are available on the NRC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NRC is classified as a small company.
Which hedge funds own NRC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NRC HEALTH's investment landscape.